Most Read Articles
01 May 2017
Body mass index (BMI), body fat and waist circumference are highly correlated, and all show an association with aggressive prostate cancer, according to a study.
21 Jun 2017
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
Roshini Claire Anthony, 20 Jun 2017

Adults with type 1 diabetes (T1D) who are prescribed metformin experience reductions in atherosclerosis progression and LDL cholesterol, according to results of the REMOVAL* study. However, the impact of metformin on glycaemic control in these patients is limited.

Christina Lau, 21 Jun 2017

Denosumab brings greater gains in spine and hip bone mineral density (BMD) than risedronate in glucocorticoid-treated patients at risk of osteoporotic fracture, according to results of a phase III study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 in Madrid, Spain.

Comparable CV safety, reduced severe hypoglycaemia risk with insulin degludec vs insulin glargine

Roshini Claire Anthony
21 Jun 2017

Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.

“[Complications] from cardiovascular disease remain an unmet clinical need for people with type 2 diabetes,” said study investigator Dr Steven Marso, chief medical officer for HCA Midwest Health cardiovascular services, Kansas City, Missouri, US, who presented the findings of the phase III, multicentre (436 sites in 20 countries), head-to-head trial at the 77th Scientific Sessions of the American Diabetes Association (ADA 2017) held in San Diego, California, US.

“[Severe] hypoglycaemia is another very relevant safety issue for both providers and patients, and it is a goal of therapy to lower glucose values in a safe and effective way to reduce microvascular complications.”

“The [DEVOTE] trial demonstrated that [insulin] degludec was as safe as [insulin] glargine with respect to cardiovascular outcomes and safer with respect to hypoglycaemia risk,” he said.

Between October 2013 and November 2014, 7,637 patients with type 2 diabetes and at high risk of major adverse cardiovascular events (MACE; mean age 65 years, mean diabetes duration 16.4 years, mean HbA1c 8.4 percent) were randomized to receive insulin degludec (n=3,818) or insulin glargine U100 (n=3,819) once daily between dinner and bedtime in addition to standard-of-care therapy. Patients were followed up for a median 2 years.

Almost 84 percent of patients were receiving insulin at baseline and 85.2 percent of patients had chronic kidney disease, cardiovascular disease, or both.

Patients on insulin degludec did not experience an increase in the incidence of cardiovascular events (composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) compared with patients on insulin glargine U100 (8.5 percent vs 9.3 percent, hazard ratio [HR], 0.91, 95 percent confidence interval [CI], 0.78–1.06; p<0.001 for noninferiority). [ADA 2017, session 3-CT-SY22; N Engl J Med 2017;doi:10.1056/NEJMoa1615692]

Patients on insulin degludec also had a 40 percent reduction in the incidence of severe hypoglycaemia compared with patients on insulin glargine U100 (4.9 percent vs 6.6 percent, rate ratio [RR], 0.60, 95 percent CI, 0.48–0.76; p<0.001 for superiority, odds ratio, 0.73, 95 percent CI, 0.60–0.89; p<0.001 for superiority), as well as a 53 percent reduction in the incidence of severe nocturnal hypoglycaemia (1.0 percent vs 1.9 percent, RR, 0.47, 95 percent CI, 0.31–0.73; p<0.001).  

“The findings of the DEVOTE study are in line with previous clinical trials comparing insulin degludec to insulin glargine U100, so we are pleased to be able to provide conclusive evidence regarding the safety of insulin degludec for patients with type 2 diabetes who are at high risk of cardiovascular complications,” said Marso.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2017
Body mass index (BMI), body fat and waist circumference are highly correlated, and all show an association with aggressive prostate cancer, according to a study.
21 Jun 2017
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
Roshini Claire Anthony, 20 Jun 2017

Adults with type 1 diabetes (T1D) who are prescribed metformin experience reductions in atherosclerosis progression and LDL cholesterol, according to results of the REMOVAL* study. However, the impact of metformin on glycaemic control in these patients is limited.

Christina Lau, 21 Jun 2017

Denosumab brings greater gains in spine and hip bone mineral density (BMD) than risedronate in glucocorticoid-treated patients at risk of osteoporotic fracture, according to results of a phase III study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 in Madrid, Spain.